M&A Deal Summary |
|
|---|---|
| Date | 2021-03-29 |
| Target | Millendo Therapeutics |
| Sector | Life Science |
| Buyer(s) | Tempest Therapeutics |
| Deal Type | Merger |
| Advisor(s) | Leerink Partners (Financial) Wilmer Cutler Pickering Hale and Dorr (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2011 |
| Sector | Life Science |
| Employees | 24 |
| Revenue | 29M USD (2023) |
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. Tempest Therapeutics is developing an inhibitor of TREX-1, a double-stranded DNA exonuclease that is designed to control activation of the cGAS/STING pathway, which is an innate immune response pathway that induces the production of IFN-?, a cytokine that is well-established to trigger the development of anti-tumor immunity. Tempest Therapeutic is based in Brisbane, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Merger M&A Deals | 1 of 1 |
| State: Michigan M&A | 1 of 1 |
| Country: United States M&A | 1 of 2 |
| Year: 2021 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-11-19 |
Factor Bioscience - Dual-CAR T Programs
Cambridge, Massachusetts, United States Factor Bioscience's Dual-CAR T Programs are specifically designed to target patients with extramedullary disease (EMD), which we are referring to as TPST-2003 and are based in Cambridge, Massachusetts. |
Buy | - |
